THE US Food and Drug Administration (FDA) last week approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, as well as other patients under certain conditions.
Mavyret is the first treatment of eight weeks duration approved for all HCV genotypes 1-6 in adult patients without cirrhosis who have not been previously treated.
Standard treatment length was previously 12 weeks or more.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 17